Assessment of a novel vegf targeted agent using patient-derived tumor tissue xenograft models of colon carcinoma with lymphatic and hepatic metastases

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Jin, Ketao ^a,b   Li, Guangliang ^a   Cui, Binbin ^c   Zhang, Jing ^a   Lan, Huanrong ^b   Han, Na ^d   Xie, Bojian ^c   Cao, Feilin ^c   He, Kuifeng ^a   Wang, Haohao ^a   Xu, Zhenzhen ^a   Teng, Lisong ^a   Zhu, Tieming ^b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c TAIZHOU HOSPITAL OF ZHEJIANG PROVINCE   (China)

^d ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FP 3; MESSENGER RNA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAF GENE; CELL PROLIFERATION; COLON CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; EFGR GENE; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LYMPH NODE METASTASIS; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE K RAS; PYROSEQUENCING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ADULT; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; COLON TUMOR; DRUG SCREENING; GENETIC ASSOCIATION; LIVER TUMOR; METABOLISM; METASTASIS; METHODOLOGY; NUCLEOTIDE SEQUENCE; NUDE MOUSE; POLYMERASE CHAIN REACTION;

ADULT; ANIMALS; CELL PROLIFERATION; COLONIC NEOPLASMS; DNA MUTATIONAL ANALYSIS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 82555202988     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028384     Document Type: Article

References (44)

1. Morton CL, Houghton PJ, (2007) Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc 2: 247-250.
2. Voskoglou-Nomikos T, Pater JL, Seymour L, (2003) Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 9: 4227-4239.
3. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, et al. (2001) Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 84: 1424-1431.
4. Sausville EA, Burger AM, (2006) Contributions of human tumor xenografts to anticancer drug development. Cancer Res 66: 3351-3354.
5. Jin K, He K, Teng F, Han N, Li G, et al. (2011) Heterogeneity in primary tumors and corresponding metastases: could it provide us with any hints to personalize cancer therapy? Pers Med 8: 175-182.
6. Gong Y, Booser DJ, Sneige N, (2005) Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 103: 1763-1769.
7. Gancberg D, Di Leo A, Cardoso F, Rouas G, Pedrocchi M, et al. (2002) Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 13: 1036-1043.
8. Regitnig P, Schippinger W, Lindbauer M, Samonigg H, Lax SF, (2004) Change of HER-2/neu status in a subset of distant metastases from breast carcinomas. J Pathol 203: 918-926.
9. Bozzetti C, Personeni N, Nizzoli R, Guazzi A, Flora M, et al. (2003) HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma. Cancer 99: 310-315.
10. Tanner M, Järvinen P, Isola J, (2001) Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res 61: 5345-5348.
11. Tapia C, Savic S, Wagner U, Schönegg R, Novotny H, et al. (2007) HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res 9: R31.
12. Akcakanat A, Sahin A, Shaye AN, Velasco MA, Meric-Bernstam F, (2008) Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases. Cancer 112: 2352-2358.
13. Wu JM, Fackler MJ, Halushka MK, Molavi DW, Taylor ME, et al. (2008) Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res 14: 1938-1946.
14. Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, et al. (2010) Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 16: 790-799.
15. Molinari F, Martin V, Saletti P, De Dosso S, Spitale A, et al. (2009) Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. Br J Cancer 100: 1087-1094.
16. Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, et al. (2004) Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 22: 4772-4778.
17. Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Pierantoni C, et al. (2007) Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options. Br J Cancer 97: 92-97.
18. Sasatomi E, Finkelstein SD, Woods JD, Bakker A, Swalsky PA, et al. (2002) Comparison of accumulated allele loss between primary tumor and lymph node metastasis in stage II non-small cell lung carcinoma: implications for the timing of lymph node metastasis and prognostic value. Cancer Res 62: 2681-2689.
19. Park S, Holmes-Tisch AJ, Cho EY, Shim YM, Kim J, et al. (2009) Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. J Thorac Oncol 4: 809-815.
20. Li Z, Jin K, Lan H, Teng L, (2011) Heterogeneity in primary colorectal cancer and its corresponding metastases: a potential reason of EGFR-targeted therapy failure? Hepatogastroenterology 58: 411-416.
21. Monaco SE, Nikiforova MN, Cieply K, Teot LA, Khalbuss WE, et al. (2010) A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases. Hum Pathol 41: 94-102.
22. Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, et al. (2009) PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 27: 2622-2629.
23. Teng LS, Jin KT, He KF, Wang HH, Cao J, et al. (2010) Advances in combination of antiangiogenic agents targeting VEGF-binding and conventional chemotherapy and radiation for cancer treatment. J Chin Med Assoc 73: 281-288.
24. Jin K, He K, Teng F, Li G, Wang H, et al. (2011) FP3: a novel VEGF blocker with antiangiogenic effects in vitro and antitumor effects in vivo. Clin Transl Oncol In press.
25. Zhang M, Zhang J, Yan M, Li H, Yang C, et al. (2008) Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choridal neovasularization in monkeys. Mol Vis 14: 37-49.
26. Zhang M, Yu D, Yang C, Xia Q, Li W, et al. (2009) The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization. Pharm Res 26: 204-210.
27. Zhang M, Zhang J, Yan M, Luo D, Zhu W, et al. (2011) A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration. Ophthalmology 118: 672-678.
28. Jin K, He K, Han N, Li G, Wang H, et al. (2011) Establishment of a PDTT xenograft model of gastric carcinoma and its application in personalized therapeutic regimen selection. Hepatogastroenterology 58 (110-111) Epub Ahead of Print. DOI 10.5754/hge11136.
29. Jin K, Teng L, Shen Y, He K, Xu Z, et al. (2010) Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review. Clin Transl Oncol 12: 473-480.
30. Jin K, He K, Li G, Teng L, (2010) Personalized cancer therapy using a patient-derived tumor tissue xenograft model: a translational field worthy of exploring further? Pers Med 7: 597-606.
31. Huynh H, Chow PK, Ooi LL, Soo KC, (2002) A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation. Cell Growth Differ 13: 115-122.
32. Wang Y, Xue H, Cutz JC, Bayani J, Mawji NR, et al. (2005) An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Lab Invest 85: 1392-1404.
33. Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, et al. (2006) Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116: 2610-2621.
34. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, et al. (2002) Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 160: 985-1000.
35. Baluk P, Morikawa S, Haskell A, Mancuso M, McDonald DM, (2003) Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol 163: 1801-1815.
36. Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, et al. (2008) Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res 14: 6456-6468.
37. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, et al. (2005) Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 7: 413-421.
38. Gibson UE, Heid CA, Williams PM, (1996) A novel method for real time quantitative RT-PCR. Genome Res 6: 995-1001.
39. Schneider S, Uchida K, Brabender J, Baldus SE, Yochim J, et al. (2005) Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. J Am Coll Surg 200: 336-344.
40. Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, et al. (2006) An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 12: 4652-4661.
41. Perez-Soler R, Kemp B, Wu QP, Mao L, Gomez J, et al. (2000) Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice. Clin Cancer Res 6: 4932-4938.
42. Teng LS, Jin KT, He KF, Wang HH, Cao J, et al. (2010) Advances in combination of antiangiogenic agents targeting VEGF-binding and conventional chemotherapy and radiation for cancer treatment. J Chin Med Assoc 73: 281-288.
43. Huang J, Frischer JS, Serur A, Kadenhe A, Yokoi A, et al. (2003) Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci USA 100: 7785-7790.
44. Baffert F, Thurston G, Rochon-Duck M, Le T, Brekken R, et al. (2004) Age-related changes in VEGF-dependency and angiopoietin-1 induced plasticity of adult blood vessels. Circ Res 94: 984-992.